Arthritis Care & Research
[DOI] [PubMed] [Google Scholar] 456.So K, McGrouther DA, Bush JA, Durani P, Taylor L, Skotny G, et al
What is the Wolverine stack
Potential Side Effects and Risks of HCG Injections HCG injections for weight loss have side effects and risks
A small number of people with lupus have joint hypermobility

PubMed ID: 10204116 GHRP-2 vs Other GHS-R1a Research Peptides Feature GHRP-2 GHRP-6 Ipamorelin Hexarelin Sequence D-Ala-D-Nal-Ala-Trp-D-Phe-Lys-NH (6aa) His-D-Trp-Ala-Trp-D-Phe-Lys-NH (6aa) Aib-His-D-2-Nal-D-Phe-Lys-NH (5aa) His-D-2-MeTrp-Ala-Trp-D-Phe-Lys-NH (6aa) GHS-R1a Activity More potent than GHRP-6 Potent (founding reference) Potent (most selective) Most potent classic GHRP CD36 Binding Yes (confirmed) Yes (confirmed) Not established Yes (confirmed) ACTH/Cortisol Release Yes (significant) Yes (significant) No (selective GH only) Yes (significant) GHRH Co-Dependency Partial Yes (82% of GH response) Partial Partial GI Motility Research Limited Yes (motilin receptor interaction) Not established Limited Cardioprotection Research Moderate Extensive None Extensive Wound Healing Research None established Published (PPAR/TGF-) None None CD36 Drug Discovery Secondary scaffold Primary scaffold None Secondary Historical Significance High-potency second-generation GHRP Discovery peptide (led to ghrelin) First selective GHRP Most potent classic GHRP GHRP-2s combination of enhanced GHS-R1a potency relative to GHRP-6, confirmed CD36 pharmacology, significant HPA axis co-stimulation, and role as a second-generation comparative reference compound makes it an essential research tool for GH axis biology, pituitary pharmacology, and cytoprotective pathway research occupying a distinct niche from the selective Ipamorelin (no HPA co-stimulation, no CD36), the more extensively CD36-characterised GHRP-6 (lower GHS-R1a potency), and the extremely potent Hexarelin (more restricted research application)
